1Gabos Z, Thoms J, Ghosh S, et al. The association between biologi- cal subtype and locoregional recurrence in newly diagnosed breast cancer[J]. Breast Cancer Res Treat, 2010,124(1 ):187-194.
2Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer[J]. Tumori, 2010,96 (1):103- 110.
3Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007,13(8): 2329-2334.
4Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistoehemistry to investigate a relationship between sub- type and short and long term survival: a collaborative analysis of data for 10 159 cases from 12 studies[J]. PLoS Med, 2010,7(5):e1000279.
5Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopansal and pestmenopansal African- American women: age-specific prevalence and survival [J]. J Surg Res, 2007,143 ( 1 ):109-118.
6Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype [J]. Ann Surg Oncol, 2009,16( 10):2705-2710.
7Nakajima H, Fujiwara I, Mizuta N, et al. Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining [J]. World J Surg, 2008,32 ( 11 ) :2477-2482.
8Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women [J]. J Surg Oncol, 2009,100(2):89-94.
9Ibrahim E, Al-Gahmi AM, Zeendin AA, et al. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estro- gen receptor, progesterone receptor, and HER-2 as surrogate markers[J]. Med Oncol, 2009,26(3):372-378.
10O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor sub- types, race, and long-term survival in the Carolina Breast Cancer Study[J]. Clin Cancer Res, 2010,16(24):6100-6110.
